Allogene Therapeutics ALLO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's operating income?
- Allogene Therapeutics (ALLO) reported operating income of -$46.09M in Q1 2026.
- How has Allogene Therapeutics's operating income changed year-over-year?
- Allogene Therapeutics's operating income increased by 29.3% year-over-year, from -$65.19M to -$46.09M.
- What is the long-term trend for Allogene Therapeutics's operating income?
- Over 4 years (2021 to 2025), Allogene Therapeutics's operating income has grown at a 3.6% compound annual growth rate (CAGR), from -$181.9M to -$209.32M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.